Israel Englander’s Arcus Biosciences RCUS Stock Holding History

Israel Englander’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,800	Closed	-$844K	–	6770
2022 Q4	$844K	Buy	+40,800	New	+$1.12M	﹤0.01%	4329
2022 Q3	–	Sell	-102,300	Closed	-$2.59M	–	7416
2022 Q2	$2.59M	Sell	102,300 -39,600	-28%	-$970K	﹤0.01%	3437
2022 Q1	$4.48M	Buy	+141,900	New	+$4.75M	﹤0.01%	3058
2021 Q2	–	Sell	-10,000	Closed	-$281K	–	7004
2021 Q1	$281K	Hold	10,000	–	–	﹤0.01%	5259
2020 Q4	$260K	Buy	+10,000	New	+$242K	﹤0.01%	4649

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Israel Englander's RCUS Position: Q2 2026 in Review

Israel Englander opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 133,110 shares worth $4.1M. The stake represents ﹤0.01% of the portfolio and ranks #3179 among its holdings. This is a return to the name: Israel Englander previously reported a position in RCUS as recently as Q4 2025.

Israel Englander first reported a position in RCUS in Q1 2018 and has held it in 29 quarters since. The position peaked at $13.8M in Q4 2024. 228 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Israel Englander held 133,110 shares of Arcus Biosciences worth $4.1M as of Q2 2026.
Arcus Biosciences was a new Israel Englander position in Q2 2026.
Arcus Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3179 holding.
Israel Englander first reported a position in Arcus Biosciences in Q1 2018 and has held it in 29 quarters since.
Israel Englander's Arcus Biosciences position peaked at $13.8M in Q4 2024.
228 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.